Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Targeted Technology Fund
AddedFeb 17, 2024
UpdatedJun 28, 2026
Targeted Technology Fund

Targeted Technology Fund

Operating

Early-stage tech investment fund focused on disruptive medical and life science innovations.

Location
San Antonio, TX, US
Founded
2009
Firm
Compare
Portfolio
Employees
Website

Targeted Technology Fund is an early-stage investment firm specializing in disruptive medical and life science innovations. The firm focuses on technologies that can significantly improve medical practices and patient outcomes, as well as those that enhance the efficiency, cost, or functionality of life science product development and manufacturing. Their typical investment rounds include Seed, Series A, Series B, and Series C stages.

Notable portfolio companies include Aerin Medical, Bi02 Medical, Bluegrass Vascular Technologies, Cardiovate, Dnatrix, StemBioSys, and Xenex. The firm prides itself on a hands-on investment philosophy, working closely with portfolio companies to accelerate their growth and success. Key partners and decision-makers bring extensive experience from leading roles in the medical and life sciences industries, ensuring valuable insights and strategic guidance for their investments.

Targeted Technology Fund - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments9
Current Portfolio Count7
Total Portfolio Exits0

Top Investment Stages

Series A2 (22.2%)
Series B2 (22.2%)
Series C2 (22.2%)
Series Unknown2 (22.2%)
Seed1 (11.1%)

Stage Mix

Series A 22%Series B 22%Series C 22%Series Unknown 22%Seed 11%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Cardiovate logo

Cardiovate

Aerin Medical logo

Aerin Medical

StemBioSys logo

StemBioSys

Xenex logo

Xenex

Dnatrix logo

Dnatrix

Bluegrass Vascular Technologies logo

Bluegrass Vascular Technologies

Bi02 Medical logo

Bi02 Medical

Targeted Technology Fund - Similar Investment Firms

Endpoint Ventures logo

Endpoint Ventures

endpoint.vc

Tachyon Ventures logo

Tachyon Ventures

tachyon.vc

Medingenii Capital logo

Medingenii Capital

medingenii.com

Tech Pioneers Fund logo

Tech Pioneers Fund

Target Global logo

Target Global

targetglobal.vc

Technology Venture Partners US logo

Technology Venture Partners US

tvp.com

MedVenture Associates logo

MedVenture Associates

Biospring Partners logo

Biospring Partners

biospring.com

Bioventures Investors logo

Bioventures Investors

Quantum Technology Partners logo

Quantum Technology Partners

Tyche Partners logo

Tyche Partners

tychepartners.com

Tech Council Ventures logo

Tech Council Ventures

VisionTech Partners logo

VisionTech Partners

Trans-Pacific Technology Fund logo

Trans-Pacific Technology Fund

tptf.co

New Technology Ventures logo

New Technology Ventures

newtechvc.com

Targeted Technology Fund - Classification

Also Known As
  • Targeted Technology Fund II, LP
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end